Диссертация (1140133), страница 16
Текст из файла (страница 16)
Jang [et al.] // J. Eur. Acad. Dermatol.Venereol. – 2010. – 24. - P. 1312–1316.124. Jo,H.Y.Co-localizationofinduciblenitricoxidesynthaseandphosphorylated Akt in the lesional skins of patients with melisma / H.Y. Jo [etal.] // J Dermatol. – 2009. – 36. – P. 10–16.125. Jones, K.
Modulation of melanogenesis by aloesin: a competitive inhibitor oftyrosinase / K. Jones [et al.] // Pigment Cell Res. – 2002. – 15. – P. 335-40.100126. Jutley, G.S. Systematic review of randomized controlled trials oninterventions for melasma: an abridged Cochrane review / G.S. Jutley [et al.]// J Am Acad Dermatol. – 2014. – 70. – P.
369-373.127. Kanechorn-Na-Ayuthaya, P. A. Topical 5% tranexamic acid for the treatmentof melasma in Asians: A double-blind randomized controlled clinical trial / P.Kanechorn-Na-Ayuthaya [et al.] // J Cosmet Laser Ther. – 2012. – 14. - 150–4.128. Kang, H.Y. In vivo reflectance confocal microscopy detects pigmentarychanges in melasma at a cellular level resolution / Kang H.Y. [et al.] // ExpDermatol. – 2010. – 19 (8). – P. 228-33.129. Kang, H.Y. Melasma and aspects of pigmentary disorders in Asians / H.Y.Kang // Ann Dermatol Venereol.
– 2012. – 4. – P. 144-147.130. Kang, H.Y. What should be considered in treatment of melasma / H.Y. Kang,J.P. Ortonne // Ann Dermatol. – 2010. – 22 (4). – P. 373-8.131. Kang, W.H. Intermittent therapy for melasma in Asian patients withcombined topical agents (retinoic acid, hydroquinone and hydrocortisone):clinical and histological studies / W.H.
Kang, S.C. Chun, S. Lee // J Dermatol.– 1998. – 25 (9). – P. 587–96.132. Kang, W.H. Melasma: histopathological characteristics in 56 Korean patients/ W.H. Kang [et al.] // Br J Dermatol. – 2002. – 146. – P. 228–237.133. Katsambas, A.Melasma. Classification and treatment / A. Katsambas, C.Antoniou // J Eur Acad Dermatol Venereol. – 1995. – 4. - P.
217-23.134. Katsambas, A.D. Depigmenting and bleaching agents: coping withhyperpigmentation / A.D. Katsambas, A.J. Stratigos // Clin Dermatol. – 2001.– 19 (4). – P. 483–8.135. Keeling, J. Mequinol 2%/tretinoin 0.01% topical solution for the treatment ofmelasma in men: a case series and review of the literature / J. Keeling [et al.]// Cutis. – 2008. – 81. – P. 179-183.101136. Khemis, A. Evaluation of efficacy and safety of rucinol serum in patients withmelasma: a randomized controlled trial / A. Khemis [et al.] // Br J Dermatol. –2007. - 156.
– P. 997-1004.137. Kim, E.H. The vascular characteristics of melasma / E.H. Kim [et al.] // JDermatol Sci. – 2007. – 46. – P. 111-116.138. Kim, J.E. Histopathological study of the treatment of melasma lesions using alow-fluence Q-switched 1064-nm neodymium:yttrium-aluminium-garnet laser/ J.E. Kim [et al.] // Clin. Exp. Dermatol. – 2013. – 38.
– P. 167–171.139. Kim, J.Y. Reduced WIF-1 expression stimulates skin hyperpigmentation inpatients with melisma / J.Y. Kim, T.R. Lee, A.Y. Lee // J. Invest. Dermatol. –2013. – 133. – P. 191–200.140. Kim, N.H. PDZK1 upregulation in estrogen-related hyperpigmentation inmelisma / N.H. Kim [et al.] // J Invest Dermatol. – 2012.
– 132. – P. 2622–2631.141. Kimball, A.B. Reduction in the appearance of facial hyperpigmentation afteruse of moisturizers with a combination of topical niacinamide and N-acetylglucosamine: results of a randomized, doubleblind, vehicle-controlled trial /A.B. Kimball [et al.] // Br J Dermatol. – 2010. – 162. – P. 435-441.142.
Kimbrough-Green, C.K. Topical retinoic acid (tretinoin) for melasma in blackpatients A vehicle-controlled clinical trial / C.K. Kimbrough-Green [et al] //Arch Dermatol. – 1994. – 130. – P. 727–733.143. Kippenberger, S. Quantification of tyrosinase, TRP-1, and Trp-2 transcripts inhuman melanocytes by reverse transcriptase-competitive multiplex PCR–regulation by steroid hormones / S. Kippenberger [et al.] // J. Invest.Dermatol. – 1998.
- 110. – P. 364–367.144. Kligman, A.M. A new formula for depigmenting human skin / A.M. Kligman,I. Willis // Arch Dermatol. – 1975. – 111. – P. 40-48.145. Lakhdar, H. Evaluation of the effectiveness of a broad-spectrum sunscreen inthe prevention of chloasma in pregnant women / H.
Lakhdar [et al.] // J EurAcad Dermatol Venereol. – 2007. – 21. – P. 738-42.102146. Lee, J. Mechanisms of melanogenesis inhibition by 2,5-dimethyl-4hydroxy3(2H)-furanone / J. Lee [et al.] // Br J Dermatol. - 2007. – 157 (2). – P. 242–8.147. Lee, J.H. Localized intradermal microinjection of tranexamic acid fortreatment of melasma in Asian patients: A preliminary clinical trial / J.H.
Lee[et al.] // Dermatol Surg. – 2006. – 32. – P. 626–31.148. Lieberman, R. Estrogen receptor expression in melasma: results from facialskin of affected patients / R. Lieberman, L. Moy // J. Drugs Dermatol. – 2008.– 7. – P. 463–465.149. Lim, J.T. Treatment of melasma using kojic acid in a gel containinghydroquinone and glycolic acid / J.T. Lim // Dermatol Surg. – 1999. – 25. – P.282-284.150. Lin, J.Y. Melanocyte biology and skin pigmentation / J.Y.
Lin, D.E. Fisher //Nature. – 2007. – 445. – P. 843-50.151. Lindsay, H.C. Chloasma uterinum / H.C. Lindsay // Arch Derm Syphilol. –1946. – 53. – P. 58.152. Lutfi, R.J. Association of melasma with thyroid autoimmunity and otherthyroidal abnormalities and their relationship to the origin of the melisma /R.J. Lutfi [et al.] // J Clin Endocrinol Metab. – 1985. – 61. – P. 28-31.153.
Mahmood, K. Role of estrogen, progesterone and prolactin in theetiopathogenesis of melasma in females / K. Mahmood [et al.] // J Pak AssocDermatol. – 2011. – 21. – P. 241–247.154. Mahmoud, B.H. Impact of long-wavelength UVA and visible light onmelanocompetent skin / B.H.
Mahmoud [et al.] // J Invest Dermatol. – 2010. –130. – P. 2092–2097.155. Mandry Pagan, R. Mandibular melisma / R. Mandry Pagan, J.L. Sanchez // PR Health Sci J. – 2000. – 19. – P. 231–234.156. Miot, L.D. Morphologic changes and the expression of alpha-melanocytestimulating hormone and melanocortin-1 receptor in melasma lesions: acomparative study / L.D. Miot [et al.] // Am. J. Dermatopathol. – 2010. – 32.– P. 676–682.103157. Miot, L.D.
Physiopathology of melasma / L.D. Miot, M.G. Silva, M. E.Marques // An Bras Dermatol. – 2009. – 84. – P. 623-35.158. Nazzaro-Porro, M. Azelaic acid / M. Nazzaro-Poro // J Am Acad Dermatol. –1987. – 17 (6). – P. 1033–41.159. Newcomer, V.D. A melanosis of the face ("chloasma") / V.D. Newcomer,M.C.
Lindberg, T.H. Sternberg // Arch Dermatol. – 1961. – 83. – P. 284–299.160. Nicolaidou,E.Pigmentationdisorders:hyperpigmentationandhypopigmentation / E. Nicolaidou, A.D. Katsambas // Clin Dermatol. – 2014.– 32. – P. 66-72.161. Nijo, T. Treatment of melasma with tranexamic acid / T. Nijo // Clin Res. –1979. – 13. – P. 3129-3131.162.
Ortonne, J.P. A global survey of the role of ultraviolet radiation and hormonalinfluences in the development of melisma / J.P. Ortonne [et al.] // J Eur AcadDermatol Venereol. – 2009. – 23. - P. 1254-1262.163. Palumbo, A. Mechanism of inhibition of melanogenesis by hydroquinone / A.Palumbo [et al.] // Biochim Biophys Acta. – 1991. – 1073 (1).
– P. 85–90.164. Passeron, T. Melasma pathogenesis and influencing factors - an overview ofthe latest research / T. Passeron // J Eur Acad Dermatol Venereol. – 2013. - 27(1). – P. 5-6.165. Patel, A.B. Clinicopathological correlation of acquired hyperpigmentarydisorders / A.B. Patel, R. Kubba, A. Kubba // Indian J Dermatol VenereolLeprol. – 2013. – 79. – P. 367-375.166. Pathak, M.A. Usefulness of retinoic acid in the treatment of melisma / M.A.Pathak, T.B. Fitzpatrick, E.W. Kraus // J Am Acad Dermatol.
– 1986. - 15. –P. 894–899.167. Pawelek, J.M. Molecular cascades in UV-induced melanogenesis: a centralrole for melanotropins? / J.M. Pawelek [et al.] // Pigment Cell Res. – 1992. –5. – P. 348–356.168. Pelletier, G. Localization of sex steroid receptors in human skin / G.Pelletier,L. Ren // Histol. Histopathol. – 2004. – 19. – P. 629–636.104169. Pérez, M. Endocrinologic profile of patients with idiopathic melisma / M.Pérez, J.L. Sánchez, F. Aguiló // J Invest Dermatol. – 1983.
– 81. – P. 543545.170. Plenck, J.J. Doctrina de Morbis CutaneisQua hi morbi in suas classes, generaet species redingtur / J. J. Plenck. - Vienna, J.F: Van Overbeke, 1776.171. Poojary, S. Tranexamic Acid in Melasma: A Review / S. Poojary, K. Minni //Pigmentary Disorders.
– 2015. – 2. – P. 228.172. Pratchyapruit, W. Instrumental analysis of the pattern of improvement andthat of recurrence of melasma in Thai females treated with Kligman-Willistriple combination therapy: confirmation by using its two different formulae /W. Pratchyapruit [et al.] // Skin Res Technol. – 2011. – 17. – P. 226-33.173. Prignano, F. Therapeutical approaches in melisma / F. Prignano [et al.] //Dermatol Clin.
– 2007. – 25 (3). – P. 337–42.174. Resnik, S. Melasma induced by oral contraceptive drugs / S. Resnik // JAMA.– 1967. – 199. – P. 601–605.175. Rigopoulos, D.Hyperpigmentation and melasma / D. Rigopoulos, S.Gregoriou, A. Katsambas // J Cosmet Dermatol. – 2007. – 6. - P. 195-202.176. Ritter,C.G.Extra-facialmelasma:clinical,histopathological,andimmunohistochemical casecontrol study / C.G.
Ritter [et al.] // J Eur AcadDermatol Venereol. – 2013. - 27(9). – P. 1088-94.177. Sacre, R.C. Melasma idiopático: avaliação das funções tireoidiana,prolactínica e gonadal feminine / R.C. Sacre [et al.] // An Bras Dermatol. –1996. – 71. – P. 195-198.178. Sanchez, N.P. Melasma: a clinical, light microscopic, ultrastructural, andimmunofluorescence study / N.P. Sanchez [et al.] // J Am Acad Dermatol.
–1981. – 4. – P. 698–710.179. Sarkar, R. Melasma in men: a clinical, aetiological and histological study / R.Sarkar [et al.] // J Eur Acad Dermatol Venereol. - 2010. – 24. – P. 768-772.180. Sarkar, R. Chemical peels for melasma in dark-skinned patients / R. Sarkar, S.Bansal, V.K. Garg // J Cutan Aesthet Surg. – 2012. – 5. – P.247-253.105181. Sarkar, R. Cosmeceuticals for Hyperpigmentation: What is Available? / R.Sarkar, P.
Arora, K.V. Garg // J Cutan Aesthet Surg. – 2013. – 6. – P. 4-11.182. Sarkar, R. Melasma update / R. Sarkar [et al.] // Indian Dermatol Online J. –2014. - 5 (4). – P. 426-35.183. Sarkar, R. Newer and upcoming therapies for melisma / R. Sarkar, S. Chugh,V.K. Garg // Indian J Dermatol Venereol Leprol. – 2012. – 78. - P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
